About Multiple Sclerosis Foundation

Home > Learn About Multiple Sclerosis > News > Drug with Regenerative Ability Studied for First Time in Humans

Drug with Regenerative Ability Studied for First Time in Humans


The first in-human study has begun on an investigational drug that researchers hope will one day be an approved treatment to repair myelin destroyed by MS. The drug, Biogen Idec's anti-LINGO-1 antibody, is designed to block a protein called LINGO-1 that interferes with the body's production of myelin.

In this Phase 1 trial, the safety and tolerability of the antibody, known as BIIB033, will be evaluated in 64 healthy adult volunteers in the Netherlands. In previous studies, the drug has shown promise in treating the effects of EAE, the mouse model of MS. More myelin growth occurred closer to the site of the antibody application in the mice, suggesting BIIB033 was responsible for the change.

Regeneration would be significant for people who already have nerve damage from MS as well as those whose disease continues to progress regardless of treatment.


  Support the MSF
Supporting MSF's programs to help make "a brighter tomorrow" has never been easier.
make a donation 

  Learn About MS
Common symptoms of MS include fatigue, weakness, spasticity, balance problems, bladder and bowel problems, numbness, vision loss, tremors and depression.
learn more 


Unless otherwise specified, all medical content is compiled by MSF staff and reviewed for accuracy by a member of our Medical Advisory Board.

The MSF strives to present clear and unbiased information. This site is partially funded through a grant from Bayer Healthcare, LLC.

© Copyright 2000-2013 Multiple Sclerosis Foundation - All Rights Reserved